2008-2011³â ±¹¹Î°Ç°­¿µ¾çÁ¶»ç ÀڷḦ ÀÌ¿ëÇÑ Çѱ¹ ¼ºÀο¡¼­ÀÇ °íÁöÇ÷ÁõÄ¡·áÁ¦ º¹¿ë¿©ºÎ¿Í Æó±â´ÉÀÇ »ó°ü °ü°è
Associations between lipid lowering agent and pulmonary function test through Korea National Health and Nutrition Examination Survey

Korean Journal of Family Practice 2015³â 5±Ç 0È£ p.188 ~ p.194

¹ÚÈñ¹Î(Park Hee-Min) - ¼¼ºê¶õ½ºº´¿ø °¡Á¤ÀÇÇаú
±è»óÈÆ(Kim Sang-Hoon) - ¼¼ºê¶õ½ºº´¿ø °¡Á¤ÀÇÇаú
ÀοäÇÑ(Linton John A.) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ °¡Á¤ÀÇÇб³½Ç
ÀÌÁö¿¬(Lee Jee-Yon) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ °¡Á¤ÀÇÇб³½Ç

Abstract

Background : Decreased pulmonary function increases the mortality rate of cardiovascular disease and total mortality rate. Statins reduce the mortality rate of cardiovascular and cerebrovascular diseases. In recent studies, statins decreased the attenuation of pulmonary function. The purpose of this study was to evaluate the relationship between use of lipid-lowering agents and pulmonary function.

Methods : This study used data from the Korea National Health and Nutrition Examination survey from years 2008 to 2011. Independent sample t-tests were performed in order to compare the results of FEV1, FVC, and FEV1/FVC in PFT between non-lipid-lowering agent users and lipid-lowering agent users. Also, multivariable logistic regression analysis was performed in order to evaluate the relationship between statin use and impairment of pulmonary function with adjustment of multi-variables.

Results : There was no statistically significant difference in PFT between lipid-lowering agent users and non-users. Lipid-lowering agent use was also insignificant when groups were divided by smoking status. Odds ratios calculated from multivariable logistic regression analysis demonstrated an insignificant correlation between lipid-lowering agent use and PFT.

Conclusion : In this study, lipid-lowering agent use did not correlate significantly with pulmonary function.

Å°¿öµå

Statin, Lipid lowering agent, PFT
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
There was no statistically significant difference in PFT between lipid-lowering agent users and non-users.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå